Visa Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Visa Inc trades at $356.1 (market cap $685.71B), while State Street SPDR S&P Biotech ETF trades at $154.46. The key difference: Visa Inc pays a 0.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| V | XBI | |
|---|---|---|
Market Cap | $685.71B | — |
Volume | 10,431,336 | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $365.14 | $164.28 |
52-Week Low | $295.52 | $85.16 |
Enterprise Value | $696.30B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations. Revenue reached $40 billion in 2025, and net income margin stands at 51.68%, reflecting robust profitability. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Visa presents a favorable long-term investment opportunity due to its dominant market position, consistent earnings growth, and high profitability. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional ownership increasing, the stock offers upside potential, though investors should monitor execution on AI initiatives and macroeconomic factors affecting consumer spending.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →